Haplotype association between GABAA receptor γ2 subunit gene (GABRG2) and methamphetamine use disorder

T. Nishiyama, M. Ikeda, Nakao Iwata, T. Suzuki, T. Kitajima, Y. Yamanouchi, Y. Sekine, M. Iyo, M. Harano, T. Komiyama, M. Yamada, I. Sora, H. Ujike, T. Inada, T. Furukawa, N. Ozaki

Research output: Contribution to journalArticlepeer-review

41 Citations (Scopus)


Psychostimulant use disorder and schizophrenia have a substantial genetic basis. Evidence from human and animal studies on the involvement of the γ-aminobutyric acid (GABA) system in methamphetamine (METH) use disorder and schizophrenia is mounting. As we tested for the association of the human GABAA receptor gamma 2 subunit gene (GABRG2) with each diagnostic group, we used a case-control design with a set of 178 subjects with METH use disorder, 288 schizophrenics and 288 controls. First, we screened 96 controls and identified six SNPs in GABRG2, three of whom we newly reported. Next, we selected two SNPs, 315C > T and 1128 + 99C > A, as representatives of the linkage disequilibrium blocks for further case-control association analysis. Although no associations were found in either allelic or genotypic frequencies, we detected a haplotypic association in GABRG2 with METH use disorder, but not with schizophrenia. This finding partly replicates a recent case-control study of GABRG2 in METH use disorder, and thus indicates that GABRG2 may be one of the susceptibility genes of METH use disorder.

Original languageEnglish
Pages (from-to)89-95
Number of pages7
JournalPharmacogenomics Journal
Issue number2
Publication statusPublished - 2005

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Genetics
  • Pharmacology


Dive into the research topics of 'Haplotype association between GABAA receptor γ2 subunit gene (GABRG2) and methamphetamine use disorder'. Together they form a unique fingerprint.

Cite this